In his new role, he will lead the growth strategy for the group’s operations, including Apothecon Pharmaceuticals in India and Navinta LLC in the United States
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
Access to genomic testing, not therapy cost, is the biggest challenge
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
Union Minister Prataprao Jadhav terms hypertension a “silent killer”; experts push for early screening, lifestyle correction and wellness-focused healthcare
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers
Subscribe To Our Newsletter & Stay Updated
